Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate the LDL C lowering and HDL C elevating efficacy of torcetrapib 60 mg administered in a fixed combination with atorvastatin 10 to 80 mg/day compared to atorvastatin alone or placebo in subjects with mixed dyslipidemia (Frederickson Types IIa and IIb). The LDL-C lowering and HDL-C elevating efficacy of the fixed combination will be tested within and across the 2 types of dyslipidemia to establish its incremental benefit over atorvastatin alone, both across and at each of 4 approved atorvastatin dose levels, and over placebo.
Critère d'inclusion
- Mixed dyslipidemia (Frederickson Types IIa and IIb)